1
|
Hammel P, El-Hariry I, Macarulla T, Garcia-Carbonero R, Metges JP, Bouché O, Portales F, Pazo Cid RA, Mineur L, Cubillo Gracian AM, Trouilloud I, Guimbaud R, Tougeron D, Reina Zoilo JJ, Feliu J, Sauri T, Fountzilas C, Kay R, Youssoufian H, Hidalgo M. Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441). J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.4_suppl.518] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
518 Background: Eryaspase, asparaginase encapsulated in red blood cells is an investigational product under development. The encapsulated asparaginase induces the degradation of asparagine and glutamine, crucial for cancer cell growth and survival. An earlier Phase 2b study in patients with advanced pancreatic cancer showed an improvement in overall survival (OS) and progression free survival (PFS) with eryaspase plus chemotherapy. Methods: TRYbeCA-1 was a randomized, open-label Phase 3 trial of eryaspase combined with chemotherapy in patients with advanced adenocarcinoma of the pancreas who have progressed on only one prior line of systemic anti-cancer therapy. Patients were randomized in a 1:1 ratio to gemcitabine/nab-paclitaxel or irinotecan/fluorouracil (5FU) therapy (depending on first-line received) with or without eryaspase, administered as IV infusion on Day 1 and Day 15 of each 4-week cycle. Key eligibility criteria included progression on or following first-line systemic treatment, ECOG performance status 0 or 1, stage III-IV disease, documented evidence of disease progression, available tumor tissue and adequate organ function. The primary endpoint was OS. A total of 412 events were required for 90% power to detect a treatment effect hazard ratio (HR) of 0.725 at a two-sided significance level of 5%. Results: A total of 512 patients were included. Baseline characteristics were well balanced between the treatment arms. The study did not meet the OS primary endpoint [HR: 0.92 (95% confidence interval (CI), 0.76-1.11), p-value 0.375]. The median OS for patients treated with eryaspase plus chemotherapy was 7.5 mo (95% CI, 6.5-8.3), compared to 6.7 mo (95% CI, 5.4-7.5) for chemotherapy alone. There was a trend of nominal OS benefit in 107 patients treated with eryaspase and irinotecan-5FU compared to 109 patients in control subgroup, with a median OS of 8.0 mo versus 5.7 mo, respectively [HR: 0.81 (95% CI: 0.60- 1.09)]. Treatment effect was consistent across various prognosis factors. Median PFS was 3.7 mo vs. 3.5 mo in the eryaspase and control arms, respectively [HR: 0.89 (95% CI: 0.73-1.07), p-value 0.215]. Disease control rate was 57.6% and 49.0% (p-value 0.047) in the eryaspase and control arms, respectively. The most common adverse events were in the eryaspase arm were asthenia, diarrhea, and anemia (Grade 3-4: 16.9%, 7.66% and 17.3%, respectively). Eryaspase did not appear to enhance toxicity of chemotherapy. Conclusion: This large prospective study did not meet it primary endpoint of improving OS in patients treated with eryaspase. The addition of eryaspase demonstrated nevertheless a well-tolerated profile and an encouraging survival benefit in the irinotecan/5FU subgroup, warranting further investigation. Clinical trial information: NCT03665441.
Collapse
Affiliation(s)
- Pascal Hammel
- Hôpital Beaujon (AP-HP), Clichy, and University Paris VII, Paris, France
| | | | | | - Rocio Garcia-Carbonero
- Oncology Department, Hospital Universitario 12 de Octubre, IIS Imas12, UCM, Madrid, Spain
| | - Jean-Philippe Metges
- CHU Brest–Institut de Cancerologie et d’Hematologie ARPEGO Network, Brest, France
| | | | | | - Roberto A. Pazo Cid
- Miguel Servet University Hospital. Aragon Institute of Health Sciences (IACS), Zaragoza, Spain
| | | | | | | | | | - David Tougeron
- Department of Gastroenterology, Poitiers University Hospital, Poitiers, France
| | | | - Jaime Feliu
- Hospital Universitario La Paz, Madrid, Spain
| | - Tamara Sauri
- Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain
| | | | - Richard Kay
- School of Pharmacy and Pharmaceutical Medicine, Wales, United Kingdom
| | | | | |
Collapse
|
2
|
Pazo Cid RA, Pardo J, Nuno-Alves A, Gurruchaga I, Alvarez M, Torres MI, Comin A, Felices MP, Martínez-Lite J, Anton A. Searching for circulating proteins as new biomarkers/potential therapeutic targets in advanced pancreatic cancer patients. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.e16219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Roberto A. Pazo Cid
- Miguel Servet University Hospital. Aragon Institute of Health Sciences (IACS), Zaragoza, Spain
| | - Julian Pardo
- Aragon Health Research Institute, Zaragoza, Spain
| | | | | | - Maria Alvarez
- Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain
| | | | - Ana Comin
- Miguel Servet University Hospital, Aragon's Health Research Institute, Zaragoza, Spain
| | | | | | - Antonio Anton
- Hospital Universitario Miguel Servet, Servicio de Oncología, Zaragoza, Spain
| |
Collapse
|
3
|
Hammel P, Lacy J, Portales F, Sobrero AF, Pazo Cid RA, Manzano Mozo JL, Terrebonne E, Dowden SD, Shiansong Li J, Ong TJ, Nydam T, Philip PA. Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC). J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.4_suppl.204] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
204 Background: In the phase 3 MPACT study, treatment with nab-P + G resulted in a > 3-fold reduction in primary pancreatic tumor burden vs G in patients with metastatic PC, suggesting the potential for activity against LAPC. This international, multicenter single arm, phase 2 trial (LAPACT) was designed to evaluate the efficacy and safety of an induction phase regimen of nab-P + G in previously untreated patients with LAPC. Methods: Treatment-naive patients with unresectable LAPC and Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 were enrolled. The induction phase was designed as 6 cycles of nab-P 125 mg/m2 + G 1000 mg/m2 on D 1, 8, and 15 of each 28-day cycle. After induction, patients without progressive disease or unacceptable adverse events were eligible for continued treatment with nab-P + G, chemoradiation, or surgery per investigator’s choice (IC). Surgery could occur prior to completing 6 induction cycles if the investigator deemed there had been a sufficient tumor response. The primary endpoint was time to treatment failure (TTF) in patients treated with nab-P + G as induction therapy followed by IC treatment. Key secondary endpoints included disease control rate (DCR), overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results: Of 107 patients enrolled, 106 were evaluable for the safety analysis. No new toxicities were identified. The most common grade ≥ 3 treatment-emergent adverse events during induction were neutropenia (42%), anemia (11%), and fatigue (10%); grade 3 peripheral neuropathy occurred in 4% of patients. The most frequent reasons for discontinuing induction were adverse events (18%) and progressive disease (7%). Forty-six (43%) patients received IC treatment after induction: 13 (12%) continued nab-P + G, 17 (16%) received chemoradiation, and 16 (15%) underwent surgical resection (R0, n = 7; R1, n = 9). DCR and ORR during induction were 78% and 35%, respectively; with a median TTF of 8.6 months and median PFS of 10.2 months. Conclusion: A nab-P + G induction regimen in LAPC appears tolerable and feasible and is associated with encouraging antitumor activity and promising TTF and PFS. NCT02301143. Clinical trial information: NCT02301143.
Collapse
Affiliation(s)
| | - Jill Lacy
- Yale School of Medicine, Yale University, New Haven, CT
| | | | | | | | - Jose Luis Manzano Mozo
- Institut Català d'Oncologia, Hospital Universitario German Trias i Pujol, Badalona, Spain
| | | | - Scot D. Dowden
- University of Calgary Tom Baker Cancer Centre, Calgary, AB, Canada
| | | | | | | | | |
Collapse
|
4
|
Hernando-Cubero J, Alvarez-Garcia N, Pazo Cid RA, Martinez Trufero J, Alvarez M, Lao Romera J, Millastre E, Bernad IP, Madani J, Gimeno J, Nuno-Alves A, Polo Marques E, Alonso V, Anton A. Prognostic models in advanced gastric cancer in first and second line chemotherapy treatment in Spanish population. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e15603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15603 Background: No globally accepted prognostic score has been developed in advanced gastric cancer (AGC). The purpose of this study is to explore baseline host or tumor related prognostic factors in spanish AGC patients in first and second line chemotherapy treatment. In addition we compare our scores with previously published scores in asian and european population. Methods: A total of 166 patients with AGC treated in our institution between 2012 and 2016 were screened. 119 received first line chemotherapy (CT) and 47 of them also received second line CT and were included in the analysis. Prognostic factors were evaluated using the Cox proportional hazard model. We use as comparators four first line and three second line scores published in literature. Results: The overal survival (OS) in first line and second line patients were 9 and 5 months. To construct first line CT score we selected four risk factors: ECOG≥2, Her2 negative, Irinotecan based CT and albumin < 3,6mg/dl. OS were 23 months in low risk group, who had zero or one risk points, 15 months for patients in the moderate risk group, who had two or three risk points, and 5 months for patients in the high risk group, who had all four risk points. In the second line CT score we included four risk factors: ECOG ≥2, albumin < 3.6mg/dl, Hb < 11.5mg/dl and CA19.9 reduction less than 30% after 2 CT cycles. OS were 30 months in low risk group, who had zero or one risk points, 16 months for patients in the moderate risk group, who had two or three risk points, and 3 months for patients in the high risk group, who had all four risk points. Conclusions: In the present study, we propose two new prognostic scores for patients with AGC developed in the same cohort and including HER2 status. This prognostic model could help clinicians choose and applicable treatment based on the stimated prognosis. [Table: see text]
Collapse
Affiliation(s)
| | | | - Roberto A. Pazo Cid
- Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | | | - Maria Alvarez
- Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain
| | | | - Esther Millastre
- Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain
| | | | - Julia Madani
- Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain
| | | | | | - Eduardo Polo Marques
- Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain
| | - Vicente Alonso
- Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain
| | - Antonio Anton
- Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain
| |
Collapse
|
5
|
Lacy J, Portales F, Hammel P, Pazo Cid RA, Manzano Mozo JL, Kim EJH, Dowden SD, Borg C, Sastre J, Bathini VG, Terrebonne E, Lopez-Trabada D, Rivera F, Asselah J, Damiani A, Hwang JJ, Ong TJ, Nydam T, Shiansong Li J, Philip PA. Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC). J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.4_suppl.358] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
358 Background: Treatment options for pts with LAPC are limited and generally similar to those for metastatic PC (mPC). The phase 3 MPACT trial of pts with mPC demonstrated a > 3-fold shrinkage of primary tumors with nab-P + G vs G, suggesting the potential of nab-P + G for LAPC treatment. Here, we present interim results on disease control rate (DCR), adverse events (AEs), and quality of life (QoL) from the international phase 2 LAPACT trial. Methods: Pts with treatment-naive unresectable LAPC and ECOG performance status of 0 or 1 received 6 cycles (C) of nab-P 125 mg/m2 + G 1000 mg/m2 on days 1, 8, and 15 of each 28-day C. After the initial nab-P + G treatment phase, pts without PD and unacceptable AEs were eligible for investigator’s choice (IC) of continued treatment with nab-P + G, chemoradiation, or surgery. Surgery could occur prior to completing 6 C in the case of a major response. Pt-reported QoL was assessed via EORTC QLQ-C30 and QLQ-PAN26 questionnaires at screening and prior to infusion on day 1 of each C. Results: As of Aug 17, 2016, 47 pts completed (28/47, 60%) or discontinued (19/47, 40%) the initial nab-P + G treatment (median, 5 C). Median age was 66 years (range, 44 - 86). The most frequent reasons for discontinuation were AE (10/47 [21%], with the most common being neutropenia and abnormal liver function [2 pts each]) and PD (3/47, 6%). The most common grade ≥ 3 AEs were neutropenia (34%) and anemia (11%). The DCR ≥ 16 weeks was 76% (34/45 efficacy-evaluable pts [defined as having evaluable baseline and ≥ 1 postbaseline scan]; PR, n = 13; SD, n = 21). Twenty-two pts (47%) were assigned by the investigators to an IC treatment: 4 (9%) to continue nab-P + G, 8 (17%) to chemoradiation, and 10 (21%) to surgical resection. Mean QoL scores remained stable during the study, with improved symptom scores for appetite and pain. During the initial nab-P + G treatment phase, most patients reported a complete resolution of certain limitations, including depression (≈ 80%), constipation (≈ 62%), and nausea (≈ 93%). Conclusions: These interim results suggest that for pts with LAPC, nab-P + G is tolerable and produces a promising DCR. On average, QoL scores remained stable during nab-P + G treatments. Clinical trial information: NCT02301143.
Collapse
Affiliation(s)
| | - Fabienne Portales
- Institut regional du Cancer de Montpellier (ICM), Montpellier, France
| | | | | | | | | | | | | | | | - Venu Gopal Bathini
- Cancer Center of Excellence - University of Massachusetts Medical School, Worcester, MA
| | | | | | - Fernando Rivera
- Hospital Universitario Marques de Valdecilla, Santander, Spain
| | - Jamil Asselah
- Mcgill University Royal Institution, Montreal, QC, Canada
| | - Azzurra Damiani
- Azienda Ospedaliera Universitaria San Martino, Genova, Italy
| | - Jimmy J. Hwang
- Department of Medicine and Oncology and Innovation Center for Biomedical Informatics, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC
| | | | | | | | | |
Collapse
|
6
|
Díaz-Serrano A, Lopez-Rios F, Dominguez C, Fonseca PJ, Angulo B, Pazo Cid RA, Plaza C, Rivera F, Rodriguez M, Leon A, Hernandez Prieto S, Paz-Ares L, Gomez-Martin C. PI3K upregulation as a negative predictive factor of survival in HER2 amplified gastric cancer treated with Trastuzumab. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e15567] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Fernando Lopez-Rios
- Laboratorio de Dianas Terapeuticas, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain
| | - Carolina Dominguez
- Laboratorio de Dianas Terapeuticas. Hospital Universitario Madrid Norte Sanchinarro, Madrid, Spain
| | | | | | - Roberto A. Pazo Cid
- Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | - Carlos Plaza
- Laboratorio de Dianas Terapeuticas, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain
| | - Fernando Rivera
- Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | | | - Ana Leon
- Oncology Department. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Susana Hernandez Prieto
- Laboratorio de Dianas Terapeuticas. Hospital Universitario Madrid Norte Sanchinarro, Madrid, Spain
| | - Luis Paz-Ares
- Hospital Universitario Doce de Octubre and CNIO, Madrid, Spain
| | | |
Collapse
|
7
|
Gomez-Martin C, Pazo Cid RA, Salud A, Fonseca PJ, Leon A, Galan M, Visa L, Rivera F, Alsina M, Plaza C, Angulo B, Hernandez Prieto S, Dominguez C, Rodriguez Garcia M, Del Valle E, Fernandez S, Rojo F, Cuatrecasas M, Lopez-Rios F. Detection of actionable oncogene drivers alterations in HER2-amplified gastric cancer by next generation sequencing. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.3_suppl.67] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
67 Background: HER2 amplified cases are the only subset of gastric carcinoma (GC) patients with an approved targeted therapy (≈20%). In GC it is still unknown if there is a mutually exclusive pattern of mutations in major driver oncogenes. We performed a systematic search for targetable oncogenes in a cohort of HER2 amplified GC patients. Methods: 53 Formalin-fixed paraffin embedded samples from HER2 amplified GC patients (43 tumor and 10 normal samples) were selected for next generation sequencing (NGS). Before DNA extraction a macrodissection procedure was performed to guarantee at least 30% tumor in all cases. DNA samples were sequenced using the Ion Torrent Personal Genome Machine (PGM) sequencing platform (Life Technologies, Carlsbad, CA, USA). The Ion AmpliSeq Cancer Hotspot Panel v2 was used. This panel encompasses more than 2800 mutational hotspots of 50 oncogenes and tumor suppressor genes. Data were processed using the Ion Torrent platform-specific pipeline software Torrent suite v4.2. Moreover, sequencing data were analyzed with Ion Reporter software 4.2 to detect any copy number alteration of the genes included in the panel. Results: We successfully sequenced all samples. We identified 89 mutations in 12 genes (range from 1 ~ 9). The most frequent significant mutations included TP53 mutations (30), PI3KCA (3), SMAD4 (3), CDKN2A (4), CTNNB1 (3) and MET (3). Other mutations were found in KRAS, NOTCH, APC, and VHL genes. We also detected potential amplifications in the KRAS (4), EGFR (9), PI3KCA (11), AKT (6), FGFR (6), CDKN2A (4) and CDH1(8) genes. Among 43 tumor specimens, 86% of specimens harbored at least one genetic alteration, most of them linked to actionable mutations or amplifications Conclusions: Within HER2 amplified GCs, there are additional subsets with a potentially targetable oncogene. Future testing for these targets will benefit from including HER2 amplified GC patients Supported by the Spanish Ministry of Health, Fondo de Investigaciones Sanitarias grant PI11/01005 and European FEDER (PN I+D+I 2008‐20011).
Collapse
Affiliation(s)
- Carlos Gomez-Martin
- Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Roberto A. Pazo Cid
- Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | | | | | - Ana Leon
- Oncology Department and Translational Oncology Division, Fundacion Jimenez Diaz Hospital, Madrid, Spain
| | - MaCarmen Galan
- Institut Catalá d´Oncologia, Hospital Duran i Reynals, Barcelona, Spain
| | - Laura Visa
- Department of Medical Oncology, Hospital Clinic, Barcelona, Spain
| | - Fernando Rivera
- Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Maria Alsina
- Hospital Universitario de Vall d'Hebron, Barcelona, Spain
| | - Carlos Plaza
- Centro Integral Oncológico Clara Campal, Madrid, Spain
| | | | - Susana Hernandez Prieto
- Laboratorio de Dianas Terapeuticas. Hospital Universitario Madrid Norte Sanchinarro, Madrid, Spain
| | - Carolina Dominguez
- Laboratorio de Dianas Terapeuticas. Hospital Universitario Madrid Norte Sanchinarro, Madrid, Spain
| | | | | | | | - Federico Rojo
- Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | | | | |
Collapse
|
8
|
Benavides M, Gallego Plazas J, Guillen C, Vera R, Iranzo V, Diaz IALES, Arevalo S, Pisa A, Martin-Richard M, Salud Salvia A, Falco E, Saenz A, Manzano JL, Pulido G, Martínez-Galán J, Pazo Cid RA, Rivera F, Garcia T, Irigoyen A, Aranda E. Gemcitabine(G)/erlotinib(E) versus gemcitabine/erlotinib/capecitabine(C) in the first-line treatment of patients with metastatic pancreatic cancer (mPC): Efficacy and safety results of a phase IIb randomized study from the Spanish TTD Collaborative Group. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.4122] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Carmen Guillen
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Ruth Vera
- Service of Medical Oncology, Hospital de Navarra, Pamplona, Spain
| | - Vega Iranzo
- Hospital General Universitario de Valencia, Valencia, Spain
| | | | | | - Aleydis Pisa
- Institut Oncològic del Vallès, Corporació Sanitària Parc Taulí - Consorci Sanitari de Terrassa, Sabadell, Spain
| | | | | | | | | | - Jose Luis Manzano
- Institut Català d'Oncologia, Hospital Universitario German Trias i Pujol, Badalona, Spain
| | - Gema Pulido
- Medical Oncology Department University Reina Sofía Hospital, Cordoba, Spain
| | | | - Roberto A. Pazo Cid
- Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | - Fernando Rivera
- Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Teresa Garcia
- Hematology and Medical Oncology Department, University Hospital Morales Meseguer, UMU, IMIB, Murcia, Spain
| | - Antonio Irigoyen
- Medical Oncology Department. Hospital Virgen de la Salud, Toledo, Spain
| | | |
Collapse
|
9
|
Pazo Cid RA, Martinez Trufero J, Lanzuela M, Fuentes J, Ubieto MA, Banzo J, Sarriá L, Artigas JM, Hördnler C, Artal A, Puértolas T, Serrablo A, Soria M, Barrao E, Cebollero A, Calera L, Pajares I, Hernández García A, Hernando Cubero J, Anton A. Role of FDG-PET-CT (PET) in predicting outcome of advanced hepatocellular carcinoma (aHCC) patients (pts) treated with sorafenib (SB): A prospective controlled study. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.4104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Roberto A. Pazo Cid
- Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | | | - M. Lanzuela
- Radiation Oncology Department, Miguel Servet University Hospital, Aragon Health Sciences Institute, Zaragoza, Spain
| | - Javier Fuentes
- Gastroenterology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | - Miguel A Ubieto
- Nuclear Medicine Department, Clinica Quiron, Zaragoza, Spain
| | - Javier Banzo
- Nuclear Medicine Department, Clinica Quiron, Zaragoza Spain, Zaragoza, Spain
| | - Luis Sarriá
- Radiology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | - José María Artigas
- Radiology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | - Carlos Hördnler
- Pathology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | - Angel Artal
- Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | - Teresa Puértolas
- Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | - Alejandro Serrablo
- General Surgery Department, Miguel Servet University Hospital, Zaragoza, Spain
| | - Maite Soria
- Gastroenterology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | - Elena Barrao
- Gastroenterology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | - Ana Cebollero
- Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | - Lourdes Calera
- Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | - Isabel Pajares
- Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | | | | | - Antonio Anton
- Hospital Universitario Miguel Servet, Zaragoza, Spain
| |
Collapse
|
10
|
Pazo Cid RA, Antón A. Advanced HER2-positive gastric cancer: current and future targeted therapies. Crit Rev Oncol Hematol 2012; 85:350-62. [PMID: 23021388 DOI: 10.1016/j.critrevonc.2012.08.008] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2012] [Accepted: 08/29/2012] [Indexed: 12/13/2022] Open
Abstract
The prognostic value of human epidermal growth factor receptor 2 (HER2) in gastric cancer is controversial. Consensus guidelines have standardized the testing of HER2 status in gastric cancer. Overexpression of this receptor occurs in approximately 20% of gastric and gastro-esophageal junction adenocarcinomas, predominantly those of the intestinal type. Recently, trastuzumab has emerged as the first targeted drug to improve overall survival when combined with chemotherapy in advanced HER2-positive gastric cancer. Primary and secondary resistance to trastuzumab has become a major problem and new strategies to overcome this resistance are needed. A high percentage of advanced HER2-positive gastric cancer patients who progress on trastuzumab therapy are candidates for second-line therapy. New families of targeted drugs, including tyrosine kinase inhibitors (TKIs) such as lapatinib and PF-00299804, mammalian target of rapamycin (mTOR) pathway inhibitors such as everolimus, heat-shock protein 90 (HSP90) inhibitors such as AUY922, HER dimerization inhibitors such as pertuzumab, and antibody-chemotherapy conjugates such as trastuzumab-emtansine (T-DM1), could offer alternative second-line treatments when trastuzumab-based first-line therapy fails.
Collapse
Affiliation(s)
- Roberto A Pazo Cid
- Aragon Institute of Health Sciences, Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain.
| | | |
Collapse
|